



POSTER PRESENTATION

Open Access

Targeted delivery to inflammatory monocytes for efficient RNAi-mediated immuno-intervention in auto-immune arthritis

Jessy Présuméy^{1,2†}, Gabriel Courties^{1,2†}, Louis-Marie Charbonnier^{1,2}, Virginie Escriou^{3,4,5,6}, Daniel Scherman^{3,4,5,6}, Yves-Marie Pers^{1,2,7}, Pascale Louis-Plence^{1,2}, Diego Kyburz⁸, Steffen Gay⁸, Christian Jorgensen^{1,2,7}, Florence Apparailly^{1,2,7*}

From 6th European Workshop on Immune-Mediated Inflammatory Diseases
Nice, France. 23-25 November 2011

Inflammatory mouse Ly6C^{high} monocyte subset and its human counterpart, defined as CD14⁺ CD16⁻, represent a valuable cellular target for innovative immunotherapeutic strategies against immune-mediated inflammatory disorders (IMID). However, delivery systems able to differentially target both subsets in vivo are still missing as well as demonstration for efficient immuno-modulation. The present work aims at providing evidences for the selective delivery of a siRNA-containing lipid formulation to the Ly-6C^{high} monocyte population and at evaluating the therapeutic potential of targeting this subset as well as their human counterpart for immuno-intervention in a prototype IMID like rheumatoid arthritis (RA). The pre-B-cell colony enhancing factor (PBEF/visfatin/Nampt) is an essential enzyme in the NAD biosynthetic pathway that exerts a key role in the persistence of inflammation through the induction of the expression of the TNF- α and IL-6 pro-inflammatory cytokines and is highly expressed in patients with a variety of IMID. Mice with collagen-induced arthritis (CIA) display Ly-6C^{high} monocytosis in the circulation that infiltrate into the inflamed joints. The systemic delivery of siRNAs formulated with the cationic liposome DMAPAP provides specific and functional down-regulation of PBEF within inflammatory monocytes. Moreover, decreased production of the PBEF-induced pro-inflammatory cytokines TNF- α and IL-6 was evidenced in both mouse and human inflammatory monocytes. PBEF gene silencing within Ly-6C^{high} monocytes resulted in reduced disease severity in mice

with CIA, associated with an overall systemic immuno-modulation of the effector T cell balance. These results identify PBEF as a critical target to modulate autoimmune responses and inflammation in arthritis and provide novel evidence that silencing of a master gene within inflammatory monocytes is a promising strategy for future therapeutic intervention in the context of IMID.

Author details

¹Inserm, U 844, CHU Saint Eloi University Hospital, Montpellier, France. ²University of Medicine, Montpellier, France. ³Inserm, U 1022, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France. ⁴CNRS, UMR8151, Paris, France. ⁵University of Pharmacy Paris Descartes, Laboratoire de Pharmacologie Chimique, Génétique et Imagerie, Paris, France. ⁶Ecole Nationale Supérieure de Chimie de Paris, Paris, France. ⁷CHU Lapeyronie University Hospital, Clinical Dept. for Osteoarticular Diseases, Montpellier, France. ⁸Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology, Zurich, Switzerland.

Published: 23 November 2011

doi:10.1186/1479-5876-9-S2-P38

Cite this article as: Présuméy et al.: Targeted delivery to inflammatory monocytes for efficient RNAi-mediated immuno-intervention in auto-immune arthritis. *Journal of Translational Medicine* 2011 **9**(Suppl 2):P38.

† Contributed equally

¹Inserm, U 844, CHU Saint Eloi University Hospital, Montpellier, France
Full list of author information is available at the end of the article